These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 12479367)

  • 21. Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy.
    Liang K; Jin W; Knuefermann C; Schmidt M; Mills GB; Ang KK; Milas L; Fan Z
    Mol Cancer Ther; 2003 Apr; 2(4):353-60. PubMed ID: 12700279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells.
    Yang CC; Lin HP; Chen CS; Yang YT; Tseng PH; Rangnekar VM; Chen CS
    J Biol Chem; 2003 Jul; 278(28):25872-8. PubMed ID: 12738789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.
    Nguyen DM; Chen GA; Reddy R; Tsai W; Schrump WD; Cole G; Schrump DS
    J Thorac Cardiovasc Surg; 2004 Feb; 127(2):365-75. PubMed ID: 14762343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells.
    Taylor JR; Lehmann BD; Chappell WH; Abrams SL; Steelman LS; McCubrey JA
    Oncotarget; 2011 Aug; 2(8):610-26. PubMed ID: 21881167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
    Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
    Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MiRNA‑542‑3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation.
    Ma T; Yang L; Zhang J
    Oncol Rep; 2015 Mar; 33(3):1215-20. PubMed ID: 25586125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death.
    Yu HG; Ai YW; Yu LL; Zhou XD; Liu J; Li JH; Xu XM; Liu S; Chen J; Liu F; Qi YL; Deng Q; Cao J; Liu SQ; Luo HS; Yu JP
    Int J Cancer; 2008 Jan; 122(2):433-43. PubMed ID: 17935137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression.
    McDonald GT; Sullivan R; Paré GC; Graham CH
    Exp Cell Res; 2010 Nov; 316(19):3197-206. PubMed ID: 20736003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells.
    Tabellini G; Cappellini A; Tazzari PL; Falà F; Billi AM; Manzoli L; Cocco L; Martelli AM
    J Cell Physiol; 2005 Feb; 202(2):623-34. PubMed ID: 15316930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel.
    Mabuchi S; Ohmichi M; Kimura A; Hisamoto K; Hayakawa J; Nishio Y; Adachi K; Takahashi K; Arimoto-Ishida E; Nakatsuji Y; Tasaka K; Murata Y
    J Biol Chem; 2002 Sep; 277(36):33490-500. PubMed ID: 12087097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.
    Nagata Y; Lan KH; Zhou X; Tan M; Esteva FJ; Sahin AA; Klos KS; Li P; Monia BP; Nguyen NT; Hortobagyi GN; Hung MC; Yu D
    Cancer Cell; 2004 Aug; 6(2):117-27. PubMed ID: 15324695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway.
    Lin MT; Lee RC; Yang PC; Ho FM; Kuo ML
    J Biol Chem; 2001 Dec; 276(52):48997-9002. PubMed ID: 11585835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
    Kataoka Y; Mukohara T; Shimada H; Saijo N; Hirai M; Minami H
    Ann Oncol; 2010 Feb; 21(2):255-262. PubMed ID: 19633047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.
    Ozbay T; Durden DL; Liu T; O'Regan RM; Nahta R
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):697-706. PubMed ID: 19636556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.
    Knuefermann C; Lu Y; Liu B; Jin W; Liang K; Wu L; Schmidt M; Mills GB; Mendelsohn J; Fan Z
    Oncogene; 2003 May; 22(21):3205-12. PubMed ID: 12761490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GSK-3beta reactivation with LY294002 sensitizes hepatoma cells to chemotherapy-induced apoptosis.
    Beurel E; Kornprobst M; Blivet-Van Eggelpoël MJ; Cadoret A; Capeau J; Desbois-Mouthon C
    Int J Oncol; 2005 Jul; 27(1):215-22. PubMed ID: 15942663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo.
    Bondar VM; Sweeney-Gotsch B; Andreeff M; Mills GB; McConkey DJ
    Mol Cancer Ther; 2002 Oct; 1(12):989-97. PubMed ID: 12481421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Starting with the ABCs: Akt in breast cancer.
    West KA; Dennis PA
    Mol Cancer Ther; 2011 Nov; 10(11):2031. PubMed ID: 22072813
    [No Abstract]   [Full Text] [Related]  

  • 40. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.